Half Year 2026 Neuren Pharmaceuticals Limited Earnings Call Transcript
Key Points
- Neuren Pharmaceuticals Ltd (NURPF) announced its first-ever dividend program, with a 90% payout of the available pool, fully franked, providing a tangible return to shareholders.
- The company maintains a strong cash position of $287 million, ensuring all NNZ-2591 programs are fully funded without the need for capital raises.
- European Commission approval for DAYBUE was secured, unlocking a $35 million milestone payment and higher royalty rates, with a commercial launch expected in Germany in Q4.
- The Koala Phase III trial for Phelan-McDermid syndrome is gaining momentum with 15 sites activated and 15 patients in screening, tracking well against the LAVENDER benchmark.
- DAYBUE sales momentum is strong, with Acadia raising guidance to $480-$510 million, and the potential for a $50 million milestone if North American sales exceed $500 million.
- The company has a robust pipeline with multiple upcoming catalysts, including FDA meetings for Pitt Hopkins and HIE, and a Japan Phase III readout for DAYBUE.
- The HIE program faces delays due to pending FDA feedback on a juvenile animal tox study, pushing the IND filing from Q4 2026 to H1 2027.
- The dividend program is linked only to DAYBUE royalties, and milestone payments are not included, limiting potential upside for shareholders.
- The Koala trial's timeline remains uncertain, with no formal guidance on top-line results, and enrollment could take up to two years based on the LAVENDER benchmark.
- The Pitt Hopkins FDA meeting is scheduled before the patient-focused meeting, which may limit alignment on trial design and could lead to further delays.
- The company has not disclosed specific European sales milestones and royalties, creating uncertainty for investors regarding future revenue streams.
- R&D expenses are expected to continue increasing, and the total cost for other pipeline programs like Pitt Hopkins and HIE remains uncertain pending FDA discussions.
Good morning, and welcome to today's investor webinar to discuss Neuren's first-half 2026 financial results and the company's first ever dividend program. My name is Gerry Zhao, Chief Business Officer at Neuren. Joining me today are our Chairman, Patrick Davies; and Chief Executive Officer, Jon Pilcher.
Jon will make the presentation followed by a Q&A session. A copy of today's presentation has been released to the ASX and is also available on our website. (Operator Instructions)
Before proceeding, please note that today's webinar will include forward-looking statements, which are subject to risks and uncertainties that may lead to different outcomes.
I'll now hand over to Jon to commence the presentation.
Thanks very much, Gerry. Good morning, everyone. Thank you for sparing your time to listen to us this morning. We are going to try and keep this to 40
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
